Related Experiment Video
Updated: Jul 4, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease
Navin K Kapur1, Jeffrey J Rade
1Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Abstract:
Therapeutic myocardial angiogenesis and arteriogenesis represent a novel treatment strategy for patients with angina refractory to traditional medical and surgical therapies. The fibroblast growth factors are a family of proteins that are known mediators of angio-/arteriogenesis. Based on promising preclinical animal data, a series of four randomized placebo-controlled clinical trials have been conducted to determine the safety and efficacy of local delivery of fibroblast growth factor 4 with the use of adenovirus-vector-mediated gene transfer to induce myocardial angio-/arteriogenesis in patients with stable angina. This review describes the scientific rationale underlying these clinical trials, provides an overview of their results, and discusses the implications for future studies.
Related Concept Videos
Gene Therapy
Gene Therapy
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...

